WVE Stock Forecast & Price Target

WAVE Life Sciences is currently in a strong financial position, with $544.6 million in cash and cash equivalents, expected to support its developmental runway into the third quarter of 2028. However, the recent competitive landscape has shifted considerably, with Sanofi's efdoralprin alfa Phase 2 establishing a new biomarker reference for the lung-disease segment and BEAM-302 retaining a 12-18 month regulatory lead. Wave's mid-2026 FDA accelerated-approval feedback is an important near-term catalyst to resolve regulatory uncertainty. Our analysis will involve reaching out to KOLs to understand the potential of INHBE inhibition in humans with obesity and how it might compare to LOF mutations, as well as remodel our Phase 2a projections to better predict VAT and total weight loss. The first three-month Phase 2a readout, expected in 2026, will likely be the most important datapoint for the WVE thesis, determining the potential impact on visceral fat reduction, which was shown to be clinically meaningful in the SELECT post-hoc analysis.

WAVE Life Sciences is a clinical-stage biotechnology company with a focus on developing RNA medicines for rare and prevalent diseases. However, their most promising asset, WVE-007, showed disappointing results in its phase 1 trial with no significant weight loss observed at 6 months and no dose-dependent effects on weight loss, visceral fat reduction, or lean mass preservation. This, coupled with the company's updated financial projections and lowered price target, raises significant uncertainty about the potential of their pipeline.